[Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis].
The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.
Aikawa
Naoki
N
Emergency and Critical Care Medicine, School of Medicine, Keio University.
Fujishima
Seitaro
S
D006801:Humans; D018805:Sepsis / Q000188:drug therapy* / Q000503:physiopathology*; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000503:physiopathology*